Delpor Selected by the NIH to Exhibit its Technology at the 2017 BIO International Convention

Delpor’s Implant Device

We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that it has been selected by the National Institutes of Health (NIH) to exhibit and showcase its technology at the upcoming International Convention of the Biotechnology Innovation Organization (BIO). The Convention will take place in San Diego, CA on June 19-22, 2017. Delpor will be exhibiting at BIO’s “Innovation Zone” along with other innovative companies.

“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners,” said Tassos Nicolaou, President and CEO of Delpor.

During the conference, Delpor expects to focus on its lead program, DLP-114 (6-month risperidone formulation for schizophrenia maintenance treatment) and on its two key implantable drug delivery technologies (PROZOR™ and NANOPOR™).

About Delpor, Inc.

Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide….

Read the full article from the Source…

Back to Top